TC Biopharm to Host Corporate Update Call on March 8th
TC Biopharm, a clinical-stage biotechnology company, will host a corporate update call on March 8, 2022, at 9:00 am ET. The call will focus on recent milestones, corporate developments, and clinical plans, with CEO Bryan Kobel facilitating the event. Investors are encouraged to submit questions ahead of time at IR@tcbiopharm.com. The company, known for its innovative allogeneic gamma-delta T cell therapies for cancer and viral infections, is currently conducting pivotal clinical trials for its therapies.
- None.
- None.
EDINBURGH, Scotland, March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it will host a corporate update call for interested parties on Tuesday, March 8, 2022 at 9:00 am ET.
The event will be available via the investor relations section of the company's website.
The call will be facilitated by Bryan Kobel, CEO, who will provide a corporate introduction as well as discuss recent milestones, technology, clinical plan overview and preclinical efforts.
Management will answer pre-submitted questions at the conclusion of prepared remarks. Investors are asked to submit their questions in advance to IR@tcbiopharm.com
About TC BioPharm, Ltd.
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a strong IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, opinions, projections or other factors, whether as a result of new information, future events or otherwise, except as required by law. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
View original content:https://www.prnewswire.com/news-releases/tc-biopharm-to-host-corporate-update-call-on-march-8th-301493960.html
SOURCE TC BioPharm
FAQ
What is the date of TC Biopharm's corporate update call?
Who will host the TC Biopharm corporate update call?
How can investors submit questions for the TC Biopharm call?
What will be discussed during the TC Biopharm corporate update call?
What therapies is TC Biopharm focusing on?
